Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome
Human Immunodeficiency Virus type 1 (HIV-1) infection and progression varies widely among individuals. Interferon-λ3 exerts anti-HIV function by activating JAK/STAT pathway-mediated innate immunity. Therefore, we aimed to investigate the association between single nucleotide polymorphisms of the int...
Gespeichert in:
| Veröffentlicht in: | Human immunology 2018-01, Vol.79 (1), p.70-75 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 75 |
|---|---|
| container_issue | 1 |
| container_start_page | 70 |
| container_title | Human immunology |
| container_volume | 79 |
| creator | Zaidane, Imane Wakrim, Lahcen Oulad Lahsen, Ahd Bensghir, Rajaa Chihab, Hajar Jadid, Fatima Zahra El fihry, Raouia Lamdini, Hassan Fayssel, Naouar Marhoum El Filali, Kamal Oudghiri, Mounia Benjelloun, Soumaya Ezzikouri, Sayeh |
| description | Human Immunodeficiency Virus type 1 (HIV-1) infection and progression varies widely among individuals. Interferon-λ3 exerts anti-HIV function by activating JAK/STAT pathway-mediated innate immunity. Therefore, we aimed to investigate the association between single nucleotide polymorphisms of the interleukin 28B (IL28B) gene, and the risk of acquisition, AIDS development and therapeutic outcome of HIV-1 in a Moroccan population.
A total of 266 HIV-1 seropositive and 158 HIV-1 seronegative subjects were enrolled. Genotyping of rs12979860 of the IL28B was performed using a predesigned TaqMan SNP genotyping assay. No significant association was found between IL28B rs12979860 polymorphism and susceptibility to HIV-1 infection and AIDS development (p > .05). However, in HIV-1 treated patients carrying CC genotype had a more pronounced high levels of CD4+ T-cell compared to subjects with TT genotype (p = .0004).
Interestingly, regarding HIV-1 viral load no significant differences between IL28B genotypes in treated and untreated patients were observed (p |
| doi_str_mv | 10.1016/j.humimm.2017.10.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1957769691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0198885917305189</els_id><sourcerecordid>1957769691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-baf46c4489743695205ff0da4810f4993c02220340aea6fd5c5e7788b33757c33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhHyDkIweyjJ3EHxyQSvnoSpU4FLhaXmdCvcRJ6o9K-wP432R3C0dOI42ed96ZeQl5yWDNgIm3u_VtCT6ENQcml9YaGHtEVkxJXTEmxGOyAqZVpVSrz8izlHYAIEE2T8kZ16BAMr0ivzdjxjhg-eVHytUHGhPjWmolgP7Eccr7GakdO3pVgh3pJoQyTh323nkc3Z7-8LEkeqTYO3pTksM5-60ffN6_oRebjze0w3scpjngmI-T8i1GO2PJ3tGpZDcFfE6e9HZI-OKhnpPvnz99u7yqrr9-2VxeXFeuFjxXW9s3wjWN0rKphW45tH0PnW0Ug77RunbAOYe6AYtW9F3rWpRSqW1dy1a6uj4nr09z5zjdFUzZBL9sPAx2xKkkw3QrpdBCswVtTqiLU0oRezNHH2zcGwbmEIDZmVMA5hDAobsEsMhePTiUbcDun-jvxxfg_QnA5c57j9Gk4yux8xFdNt3k_-_wB1p4mGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1957769691</pqid></control><display><type>article</type><title>Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Zaidane, Imane ; Wakrim, Lahcen ; Oulad Lahsen, Ahd ; Bensghir, Rajaa ; Chihab, Hajar ; Jadid, Fatima Zahra ; El fihry, Raouia ; Lamdini, Hassan ; Fayssel, Naouar ; Marhoum El Filali, Kamal ; Oudghiri, Mounia ; Benjelloun, Soumaya ; Ezzikouri, Sayeh</creator><creatorcontrib>Zaidane, Imane ; Wakrim, Lahcen ; Oulad Lahsen, Ahd ; Bensghir, Rajaa ; Chihab, Hajar ; Jadid, Fatima Zahra ; El fihry, Raouia ; Lamdini, Hassan ; Fayssel, Naouar ; Marhoum El Filali, Kamal ; Oudghiri, Mounia ; Benjelloun, Soumaya ; Ezzikouri, Sayeh</creatorcontrib><description>Human Immunodeficiency Virus type 1 (HIV-1) infection and progression varies widely among individuals. Interferon-λ3 exerts anti-HIV function by activating JAK/STAT pathway-mediated innate immunity. Therefore, we aimed to investigate the association between single nucleotide polymorphisms of the interleukin 28B (IL28B) gene, and the risk of acquisition, AIDS development and therapeutic outcome of HIV-1 in a Moroccan population.
A total of 266 HIV-1 seropositive and 158 HIV-1 seronegative subjects were enrolled. Genotyping of rs12979860 of the IL28B was performed using a predesigned TaqMan SNP genotyping assay. No significant association was found between IL28B rs12979860 polymorphism and susceptibility to HIV-1 infection and AIDS development (p > .05). However, in HIV-1 treated patients carrying CC genotype had a more pronounced high levels of CD4+ T-cell compared to subjects with TT genotype (p = .0004).
Interestingly, regarding HIV-1 viral load no significant differences between IL28B genotypes in treated and untreated patients were observed (p < .05).
IL28B rs12979860 polymorphism not influences the susceptibility to HIV-1 and the AIDS development. However, this polymorphism may affect the response to treatment as measured by CD4+ T cell counts.</description><identifier>ISSN: 0198-8859</identifier><identifier>EISSN: 1879-1166</identifier><identifier>DOI: 10.1016/j.humimm.2017.10.011</identifier><identifier>PMID: 29080719</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acquired Immunodeficiency Syndrome - immunology ; Acquired Immunodeficiency Syndrome - therapy ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; AIDS ; Antiretroviral Therapy, Highly Active ; CD4+ T ; CD4-Positive T-Lymphocytes - immunology ; Female ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; HAART ; HIV Seropositivity ; HIV-1 - physiology ; Humans ; Interferon-λ3 ; Interferons ; Interleukins - genetics ; Male ; Middle Aged ; Morocco ; Polymorphism, Single Nucleotide ; Treatment Outcome ; Viral Load - genetics ; Young Adult</subject><ispartof>Human immunology, 2018-01, Vol.79 (1), p.70-75</ispartof><rights>2017 American Society for Histocompatibility and Immunogenetics</rights><rights>Copyright © 2017 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-baf46c4489743695205ff0da4810f4993c02220340aea6fd5c5e7788b33757c33</citedby><cites>FETCH-LOGICAL-c362t-baf46c4489743695205ff0da4810f4993c02220340aea6fd5c5e7788b33757c33</cites><orcidid>0000-0002-3982-6163</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0198885917305189$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29080719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaidane, Imane</creatorcontrib><creatorcontrib>Wakrim, Lahcen</creatorcontrib><creatorcontrib>Oulad Lahsen, Ahd</creatorcontrib><creatorcontrib>Bensghir, Rajaa</creatorcontrib><creatorcontrib>Chihab, Hajar</creatorcontrib><creatorcontrib>Jadid, Fatima Zahra</creatorcontrib><creatorcontrib>El fihry, Raouia</creatorcontrib><creatorcontrib>Lamdini, Hassan</creatorcontrib><creatorcontrib>Fayssel, Naouar</creatorcontrib><creatorcontrib>Marhoum El Filali, Kamal</creatorcontrib><creatorcontrib>Oudghiri, Mounia</creatorcontrib><creatorcontrib>Benjelloun, Soumaya</creatorcontrib><creatorcontrib>Ezzikouri, Sayeh</creatorcontrib><title>Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome</title><title>Human immunology</title><addtitle>Hum Immunol</addtitle><description>Human Immunodeficiency Virus type 1 (HIV-1) infection and progression varies widely among individuals. Interferon-λ3 exerts anti-HIV function by activating JAK/STAT pathway-mediated innate immunity. Therefore, we aimed to investigate the association between single nucleotide polymorphisms of the interleukin 28B (IL28B) gene, and the risk of acquisition, AIDS development and therapeutic outcome of HIV-1 in a Moroccan population.
A total of 266 HIV-1 seropositive and 158 HIV-1 seronegative subjects were enrolled. Genotyping of rs12979860 of the IL28B was performed using a predesigned TaqMan SNP genotyping assay. No significant association was found between IL28B rs12979860 polymorphism and susceptibility to HIV-1 infection and AIDS development (p > .05). However, in HIV-1 treated patients carrying CC genotype had a more pronounced high levels of CD4+ T-cell compared to subjects with TT genotype (p = .0004).
Interestingly, regarding HIV-1 viral load no significant differences between IL28B genotypes in treated and untreated patients were observed (p < .05).
IL28B rs12979860 polymorphism not influences the susceptibility to HIV-1 and the AIDS development. However, this polymorphism may affect the response to treatment as measured by CD4+ T cell counts.</description><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Acquired Immunodeficiency Syndrome - therapy</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>AIDS</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>CD4+ T</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>HAART</subject><subject>HIV Seropositivity</subject><subject>HIV-1 - physiology</subject><subject>Humans</subject><subject>Interferon-λ3</subject><subject>Interferons</subject><subject>Interleukins - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morocco</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Treatment Outcome</subject><subject>Viral Load - genetics</subject><subject>Young Adult</subject><issn>0198-8859</issn><issn>1879-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EokvhHyDkIweyjJ3EHxyQSvnoSpU4FLhaXmdCvcRJ6o9K-wP432R3C0dOI42ed96ZeQl5yWDNgIm3u_VtCT6ENQcml9YaGHtEVkxJXTEmxGOyAqZVpVSrz8izlHYAIEE2T8kZ16BAMr0ivzdjxjhg-eVHytUHGhPjWmolgP7Eccr7GakdO3pVgh3pJoQyTh323nkc3Z7-8LEkeqTYO3pTksM5-60ffN6_oRebjze0w3scpjngmI-T8i1GO2PJ3tGpZDcFfE6e9HZI-OKhnpPvnz99u7yqrr9-2VxeXFeuFjxXW9s3wjWN0rKphW45tH0PnW0Ug77RunbAOYe6AYtW9F3rWpRSqW1dy1a6uj4nr09z5zjdFUzZBL9sPAx2xKkkw3QrpdBCswVtTqiLU0oRezNHH2zcGwbmEIDZmVMA5hDAobsEsMhePTiUbcDun-jvxxfg_QnA5c57j9Gk4yux8xFdNt3k_-_wB1p4mGw</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Zaidane, Imane</creator><creator>Wakrim, Lahcen</creator><creator>Oulad Lahsen, Ahd</creator><creator>Bensghir, Rajaa</creator><creator>Chihab, Hajar</creator><creator>Jadid, Fatima Zahra</creator><creator>El fihry, Raouia</creator><creator>Lamdini, Hassan</creator><creator>Fayssel, Naouar</creator><creator>Marhoum El Filali, Kamal</creator><creator>Oudghiri, Mounia</creator><creator>Benjelloun, Soumaya</creator><creator>Ezzikouri, Sayeh</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3982-6163</orcidid></search><sort><creationdate>201801</creationdate><title>Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome</title><author>Zaidane, Imane ; Wakrim, Lahcen ; Oulad Lahsen, Ahd ; Bensghir, Rajaa ; Chihab, Hajar ; Jadid, Fatima Zahra ; El fihry, Raouia ; Lamdini, Hassan ; Fayssel, Naouar ; Marhoum El Filali, Kamal ; Oudghiri, Mounia ; Benjelloun, Soumaya ; Ezzikouri, Sayeh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-baf46c4489743695205ff0da4810f4993c02220340aea6fd5c5e7788b33757c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Acquired Immunodeficiency Syndrome - therapy</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>AIDS</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>CD4+ T</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>HAART</topic><topic>HIV Seropositivity</topic><topic>HIV-1 - physiology</topic><topic>Humans</topic><topic>Interferon-λ3</topic><topic>Interferons</topic><topic>Interleukins - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morocco</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Treatment Outcome</topic><topic>Viral Load - genetics</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaidane, Imane</creatorcontrib><creatorcontrib>Wakrim, Lahcen</creatorcontrib><creatorcontrib>Oulad Lahsen, Ahd</creatorcontrib><creatorcontrib>Bensghir, Rajaa</creatorcontrib><creatorcontrib>Chihab, Hajar</creatorcontrib><creatorcontrib>Jadid, Fatima Zahra</creatorcontrib><creatorcontrib>El fihry, Raouia</creatorcontrib><creatorcontrib>Lamdini, Hassan</creatorcontrib><creatorcontrib>Fayssel, Naouar</creatorcontrib><creatorcontrib>Marhoum El Filali, Kamal</creatorcontrib><creatorcontrib>Oudghiri, Mounia</creatorcontrib><creatorcontrib>Benjelloun, Soumaya</creatorcontrib><creatorcontrib>Ezzikouri, Sayeh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaidane, Imane</au><au>Wakrim, Lahcen</au><au>Oulad Lahsen, Ahd</au><au>Bensghir, Rajaa</au><au>Chihab, Hajar</au><au>Jadid, Fatima Zahra</au><au>El fihry, Raouia</au><au>Lamdini, Hassan</au><au>Fayssel, Naouar</au><au>Marhoum El Filali, Kamal</au><au>Oudghiri, Mounia</au><au>Benjelloun, Soumaya</au><au>Ezzikouri, Sayeh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome</atitle><jtitle>Human immunology</jtitle><addtitle>Hum Immunol</addtitle><date>2018-01</date><risdate>2018</risdate><volume>79</volume><issue>1</issue><spage>70</spage><epage>75</epage><pages>70-75</pages><issn>0198-8859</issn><eissn>1879-1166</eissn><abstract>Human Immunodeficiency Virus type 1 (HIV-1) infection and progression varies widely among individuals. Interferon-λ3 exerts anti-HIV function by activating JAK/STAT pathway-mediated innate immunity. Therefore, we aimed to investigate the association between single nucleotide polymorphisms of the interleukin 28B (IL28B) gene, and the risk of acquisition, AIDS development and therapeutic outcome of HIV-1 in a Moroccan population.
A total of 266 HIV-1 seropositive and 158 HIV-1 seronegative subjects were enrolled. Genotyping of rs12979860 of the IL28B was performed using a predesigned TaqMan SNP genotyping assay. No significant association was found between IL28B rs12979860 polymorphism and susceptibility to HIV-1 infection and AIDS development (p > .05). However, in HIV-1 treated patients carrying CC genotype had a more pronounced high levels of CD4+ T-cell compared to subjects with TT genotype (p = .0004).
Interestingly, regarding HIV-1 viral load no significant differences between IL28B genotypes in treated and untreated patients were observed (p < .05).
IL28B rs12979860 polymorphism not influences the susceptibility to HIV-1 and the AIDS development. However, this polymorphism may affect the response to treatment as measured by CD4+ T cell counts.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29080719</pmid><doi>10.1016/j.humimm.2017.10.011</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3982-6163</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0198-8859 |
| ispartof | Human immunology, 2018-01, Vol.79 (1), p.70-75 |
| issn | 0198-8859 1879-1166 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1957769691 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Acquired Immunodeficiency Syndrome - immunology Acquired Immunodeficiency Syndrome - therapy Adolescent Adult Aged Aged, 80 and over AIDS Antiretroviral Therapy, Highly Active CD4+ T CD4-Positive T-Lymphocytes - immunology Female Gene Frequency Genetic Predisposition to Disease Genotype HAART HIV Seropositivity HIV-1 - physiology Humans Interferon-λ3 Interferons Interleukins - genetics Male Middle Aged Morocco Polymorphism, Single Nucleotide Treatment Outcome Viral Load - genetics Young Adult |
| title | Interleukin 28B rs12979860 genotype and Human Immunodeficiency Virus type 1: Susceptibility, AIDS development and therapeutic outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A16%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin%2028B%20rs12979860%20genotype%20and%20Human%20Immunodeficiency%20Virus%20type%201:%20Susceptibility,%20AIDS%20development%20and%20therapeutic%20outcome&rft.jtitle=Human%20immunology&rft.au=Zaidane,%20Imane&rft.date=2018-01&rft.volume=79&rft.issue=1&rft.spage=70&rft.epage=75&rft.pages=70-75&rft.issn=0198-8859&rft.eissn=1879-1166&rft_id=info:doi/10.1016/j.humimm.2017.10.011&rft_dat=%3Cproquest_cross%3E1957769691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1957769691&rft_id=info:pmid/29080719&rft_els_id=S0198885917305189&rfr_iscdi=true |